Remicade™
Active ingredients: infliximab
Pack: Remicade 100 mg powder for injection, 1 vial
Consumer medicine information
Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.
Listen to the audio transcription of the CMI leaflet.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
Rheumatoid Arthritis in Adults: Remicade, in combination with methotrexate, is indicated for the reduction of signs and symptoms and prevention of structural joint damage (erosions and joint space narrowing) in: patients with active disease despite treatment with methotrexate; patients with active disease who have not previously received methotrexate. Remicade should be given in combination with methotrexate. Efficacy and safety in Rheumatoid Arthritis have been demonstrated only in combination with methotrexate. Ankylosing Spondylitis: Remicade is indicated for the reduction of signs and symptoms and improvement in physical function in patients with active disease. Psoriatic arthritis: Remicade is indicated for the treatment of the signs and symptoms, as well as for the improvement in physical function in adult patients with active and progressive psoriatic arthritis who have responded inadequately to disease-modifying anti-rheumatic drug (DMARD) therapy. Remicade may be administered in combination with methotrexate. Psoriasis: Remicade is indicated for the treatment of adult patients with moderate to severe plaque psoriasis for whom phototherapy or conventional systemic treatments have been inadequate or are inappropriate. Safety and efficacy beyond 12 months have not been established. Crohn's Disease in Adults and in Children and adolescents (6-17 years): Remicade is indicated for the treatment of moderate to severe Crohn's disease, to reduce the signs and symptoms and to induce and maintain clinical remission in patients who have an inadequate response to conventional therapies. Refractory Fistulising Crohn's Disease: Remicade is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients. Ulcerative colitis in Adults and in Children and adolescents (6 to 17 years); Remicade is indicated for the treatment of moderately severe to severe active ulcerative colitis in patients who have had an inadequate response to conventional therapy.
Source: ARTG
Storage conditions
- Shelf lifetime is 3 Years
- Store at 2 to 8 degrees Celsius
Source: ARTG
How to use this medicine
Non-composite pack
This medicine contains one component only.
Component
- Injection, powder for
- Intravenous Infusion
- White solid, with no evidence of meltback; free of foreign particles.
Source: ARTG
Do I need a prescription?
Not scheduled medicines: We are unable to tell you if you need a prescription for these medicines. You can ask your pharmacist. These medicines are Not Scheduled.
Source: ARTG
Is this medicine subsidised?
This medicine was verified as available on the Pharmaceutical Benefits Scheme (PBS) on 1 August 2026, under the following PBS item codes:
- 9613Y (Opens in new tab)
- 5753T (Opens in new tab)
- 11482H (Opens in new tab)
- 5758C (Opens in new tab)
- 9654D (Opens in new tab)
- 6496X (Opens in new tab)
- 10184B (Opens in new tab)
- 11483J (Opens in new tab)
- 5755X (Opens in new tab)
- 4284L (Opens in new tab)
- 5754W (Opens in new tab)
- 10196P (Opens in new tab)
- 11498E (Opens in new tab)
- 11389K (Opens in new tab)
- 11490R (Opens in new tab)
- 11489Q (Opens in new tab)
- 11399Y (Opens in new tab)
- 11590B (Opens in new tab)
- 11606W (Opens in new tab)
- 10057H (Opens in new tab)
- 9612X (Opens in new tab)
- 5757B (Opens in new tab)
- 11424G (Opens in new tab)
- 10067W (Opens in new tab)
- 6397Q (Opens in new tab)
- 11497D (Opens in new tab)
- 6448J (Opens in new tab)
- 11459D (Opens in new tab)
- 5756Y (Opens in new tab)
- 9617E (Opens in new tab)
- 9674E (Opens in new tab)
- 11797X (Opens in new tab)
- 11448M (Opens in new tab)
- 11412P (Opens in new tab)
- 11445J (Opens in new tab)
- 11449N (Opens in new tab)
- 11450P (Opens in new tab)
Ask your pharmacist or doctor about your eligibility
Source: PBS
Pregnant or planning a pregnancy?
For the active ingredient: infliximab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Source: AHT
Reporting side effects
If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).
You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)
Source: ARTG
Data sources
- Australian Health Thesaurus (AHT) (Opens in new tab) – Last updated on 3 August 2026
- Australian Medicines Terminology (AMT) (Opens in new tab) – Last updated on 3 August 2026
- Australian Register of Therapeutic Goods (ARTG) (Opens in new tab) – Last updated on 3 August 2026
- Pharmaceutical Benefits Scheme (PBS) (Opens in new tab) – Last updated on 3 August 2026
- Medicines Information Pty Ltd (Opens in new tab) – Last updated on 4 March 2026
Disclaimer
Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).
Symptom Checker
Worried about your health?
Select a symptom, answer some questions, get advice